SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists

Rahul Jaswaney; Samantha Sokoloff; Val Rakita; Daniel J Rubin

doi:10.3949/ccjm.91a.23093

SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists

Cleve Clin J Med. 2024 Jul 1;91(7):415-423. doi: 10.3949/ccjm.91a.23093.

Authors

Rahul Jaswaney¹, Samantha Sokoloff², Val Rakita³, Daniel J Rubin⁴

Affiliations

¹ Fellow, Section of Cardiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
² Fellow, Section of Endocrinology, Diabetes and Metabolism, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
³ Associate Professor of Medicine; Associate Medical Director, Mechanical Circulatory Support Program; Director, CardioMEMS Program, Advanced Heart Failure, MCS, and Transplant Cardiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
⁴ Professor of Medicine, Interim Co-Director for the Center for Biostatistics and Epidemiology, Director of Clinical Research, and Deputy Chief, Section of Endocrinology, Diabetes and Metabolism, Lewis Katz School of Medicine at Temple University, Philadelphia, PA Daniel.rubin@tuhs.temple.edu.

PMID: 38950981
DOI: 10.3949/ccjm.91a.23093

Abstract

Despite current therapies, heart failure and chronic kidney disease continue to be major causes of morbidity and mortality. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have recently become standard-of-care therapy for these conditions. This review summarizes important randomized controlled trials of SGLT-2 inhibitors and guidelines for using these agents in patients with heart failure and chronic kidney disease in both clinic and hospital settings.

Publication types

Review

MeSH terms

Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy
Heart Failure* / drug therapy
Humans
Randomized Controlled Trials as Topic
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors